Bayesian decision analysis for choosing between diagnostic/prognostic prediction procedures.
暂无分享,去创建一个
John Kornak | Ying Lu | J. Kornak | Ying Lu
[1] O. Johnell,et al. The risk and burden of vertebral fractures in Sweden , 2004, Osteoporosis International.
[2] Joseph A Johnston,et al. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia , 2007, BMC women's health.
[3] Anthony O'Hagan,et al. The probability of cost-effectiveness , 2002, BMC medical research methodology.
[4] B. Muthén,et al. A Bayesian approach to nonlinear latent variable models using the Gibbs sampler and the metropolis-hastings algorithm , 1998 .
[5] S. Cummings,et al. Bone density at various sites for prediction of hip fractures , 1993, The Lancet.
[6] D. Lindley. The choice of sample size , 1997 .
[7] J. Kanis,et al. DIAGNOSIS OF OSTEOPOROSIS , 2016 .
[8] J. Bernardo. Statistical inference as a decision problem: the choice of sample size , 1997 .
[9] Giovanni Parmigiani,et al. Uncertainty and the value of diagnostic information, with application to axillary lymph node dissection in breast cancer , 2004, Statistics in medicine.
[10] Robert Kane,et al. Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women , 2005, Annals of Internal Medicine.
[11] R Simon,et al. Bayesian Design and Analysis of Active Control Clinical Trials , 1999, Biometrics.
[12] Hua Jin,et al. A Procedure for Determining Whether a Simple Combination of Diagnostic Tests May Be Noninferior to the Theoretical Optimum Combination , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[13] Lee R. Mobley,et al. Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[14] Paul Kind,et al. Measuring Population Health: A Comparison Of Three Generic Health Status Measures , 2003, Medical care.
[15] Adrian F. M. Smith,et al. Evidence-based medicine as Bayesian decision-making. , 2000, Statistics in medicine.
[16] Anthony O'Hagan,et al. Kendall's Advanced Theory of Statistics, volume 2B: Bayesian Inference, second edition , 2004 .
[17] A O'Hagan,et al. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies , 2002, Statistical methods in medical research.
[18] Marek Ancukiewicz,et al. Decision Models in Clinical Recommendations Development : the Stroke Prevention Policy , 1996 .
[19] S. Cummings,et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.
[20] Dimitris Fouskakis,et al. Comparing Stochastic Optimization Methods for Variable Selection in Binary Outcome Prediction, With Application to Health Policy , 2008 .
[21] S. Gabriel,et al. Mortality, Disability, and Nursing Home Use for Persons with and without Hip Fracture: A Population‐Based Study , 2002, Journal of the American Geriatrics Society.
[22] Hua Jin,et al. Permutation test for non-inferiority of the linear to the optimal combination of multiple tests. , 2009, Statistics and Probability Letters.
[23] M. Pepe. The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .
[24] Mu Zhu. The Counter-intuitive Non-informative Prior for the Bernoulli Family , 2004 .
[25] Magnus Johannesson,et al. Swedish population health-related quality of life results using the EQ-5D , 2004, Quality of Life Research.
[26] E. Arias,et al. United States life tables, 2004. , 2007, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[27] Patrick S. Carroll. Making Decisions (Second Edition). By D. V. Lindley. Wiley 1985. 207 pages. , 1986 .
[28] A J Moskowitz,et al. Bayesian estimation of cost-effectiveness ratios from clinical trials. , 1999, Health economics.
[29] Peter Müller,et al. Screening designs for drug development. , 2007, Biostatistics.
[30] Anthony O'Hagan,et al. INCORPORATION OF GENUINE PRIOR INFORMATION IN COST-EFFECTIVENESS ANALYSIS OF CLINICAL TRIAL DATA , 2002, International Journal of Technology Assessment in Health Care.
[31] S. Gabriel,et al. Direct Medical Costs Attributable to Osteoporotic Fractures , 2002, Osteoporosis International.
[32] B W Brown,et al. The sample size for a clinical trial: A Bayesian–decision theoretic approach , 2001, Statistics in medicine.
[33] Stephen G. Walker,et al. How many samples?: A Bayesian nonparametric approach , 2003 .
[34] J. Kanis,et al. Economic Evaluation of Interventions for Osteoporosis , 2002, Osteoporosis International.
[35] O Johnell,et al. Intervention thresholds for osteoporosis. , 2002, Bone.
[36] A O'Hagan,et al. A framework for cost-effectiveness analysis from clinical trial data. , 2001, Health economics.
[37] R. G. Murray,et al. Bayesian analysis of stress thallium-201 scintigraphy , 2004, European Journal of Nuclear Medicine.
[38] D. Draper,et al. Bayesian variable selection using cost-adjusted BIC, with application to cost-effective measurement of quality of health care , 2009, 0908.2313.
[39] D K Stangl,et al. Prediction and decision making using Bayesian hierarchical models. , 1995, Statistics in medicine.
[40] Xiao-Hua Zhou,et al. Statistical Methods in Diagnostic Medicine , 2002 .
[41] Ego Seeman,et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.
[42] A O'Hagan,et al. Bayesian cost‐effectiveness analysis from clinical trial data , 2001, Statistics in medicine.
[43] Rachael L. Fleurence,et al. The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis , 2012, PharmacoEconomics.
[44] Dimitris Fouskakis,et al. A Case Study of Stochastic Optimization in Health Policy: Problem Formulation and Preliminary Results , 2000, J. Glob. Optim..
[45] D R Shapiro,et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.
[46] Anthony O’Hagan,et al. Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio , 2000, PharmacoEconomics (Auckland).
[47] David Lindley,et al. Decision analysis and bioequivalence trials , 1998 .
[48] A. F. Smith,et al. Exploratory thoughts on clinical trials with utilities. , 1998, Statistics in medicine.
[49] J. Kanis,et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.
[50] T. Pham-Gia,et al. On Bayesian analysis, Bayesian decision theory and the sample size problem , 1997 .
[51] Dalene K Stangl,et al. Bridging the gap between statistical analysis and decision making in public health research , 2005, Statistics in medicine.
[52] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[53] Mu Zhu,et al. The Counter-intuitive Non-informative Prior for the Bernoulli Family , 2004 .
[54] D. Draper,et al. Stochastic Optimization: a Review , 2002 .
[55] T. M. Kashner,et al. Survival experience of aged hip fracture patients. , 1989, American journal of public health.
[56] Michael C. Nevitt,et al. Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial , 2001 .
[57] P. Müller. Simulation Based Optimal Design , 2005 .
[58] Andrew Gelman,et al. Data Analysis Using Regression and Multilevel/Hierarchical Models , 2006 .